key: cord-0895293-z05ykgoj authors: Mitchell, William B.; Davila, Jennifer; Keenan, Janine; Jackson, Jenai; Tal, Adit; Morrone, Kerry A.; Silver, Ellen J.; O'Brien, Sarah; Manwani, Deepa title: Children and young adults hospitalized for severe COVID‐19 exhibit thrombotic coagulopathy date: 2021-03-04 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28975 sha: 1623f99c26eb7aa6b2d05e222beade2219b7270c doc_id: 895293 cord_uid: z05ykgoj We report the clinical and laboratory coagulation characteristics of 27 pediatric and young adult patients (2 months to 21 years) treated for symptomatic COVID‐19 at a children's hospital in the Bronx, New York, between March 1 and May 31, 2020. D‐Dimer was > 0.5 μg/mL (upper limit of normal) in 25 (93%) patients at admission; 11 (41%) developed peak D‐dimer > 5 μg/mL during admission. Seven (26%) patients developed venous thromboembolism: three with deep vein thrombosis and four with pulmonary embolism. Requirement of increased ventilatory support was a risk factor for thrombosis (P = 0.006). Three of eight (38%) patients on prophylactic anticoagulation developed thrombosis; however, no patients developed VTE on low‐molecular‐weight heparin prophylaxis titrated to anti‐Xa level. Manifestation of COVID‐19 disease was severe or critical in 16 (59%) patients. Four (15%) patients died of COVID‐19 complications: all had comorbidities. Elevated D‐dimer and increased VTE rate were observed in this young cohort, particularly in those with severe respiratory complications, suggesting thrombotic coagulopathy. More data are needed to guide thromboprophylaxis in this age group. were also calculated for these comparisons. Additionally, a logistic regression analysis including the variables found to be significant in bivariate analyses was run to control for confounding and determine which factors independently predicted thrombosis. For each analysis, any cases with missing data were excluded. This cohort of 27 children and young adults hospitalized with symptomatic COVID-19 (Table 1) there are known higher rates of infection, morbidity, and mortality in these populations. 16, 17 Contrary to expectations, sickle cell disease was not associated with an increased risk of thrombosis: none of five patients developed VTE (Supporting Information Table S1 ). SCD and non-SCD patients did not In the course of the pandemic, it was difficult logistically to obtain imaging with either sonography or CT scan for patients with COVID-19 due to isolation precautions. This limited our ability to determine the absolute incidence of VTE. As our guidelines evolved, imaging was recommended for all patients but was still not uniformly available. Figure S1 ). It must be pointed out that these institutional guidelines for thromboprophylaxis management evolved as the cohort accrued and as more adult data In conclusion, although many children and young adults may not require admission to the hospital for COVID-19, the laboratory picture and clinical course of more severely ill children and young adults is similar to that of older adult patients. Coagulopathy, elevated D-dimer, and increased VTE rate were observed in this young cohort, particularly in those with severe respiratory complications. More data are needed to guide thromboprophylaxis in this age group. However, until more data from larger studies are available, care will continue to be guided by the adult experience. In this time of limited experience with this novel infection, we have closely observed our patients to guide us in how best to care for them. We hope our findings will inform future management of children and young adults hospitalized with symptomatic COVID-19. WBM collected and analyzed data and wrote the manuscript, JJ collected data, JD collected data and revised the manuscript, AT collected data and revised the manuscript, KAM revised the manuscript, EJS performed statistical analyses, SOB analyzed data and revised the manuscript, and DM oversaw data collection, analyzed data, and revised the manuscript. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Coagulopathy of coronavirus disease Coagulopathy in COVID-19 The coagulopathy, endotheliopathy, and vasculitis of COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review Epidemiology of COVID-19 among children in China Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status COVID-19 in Italian pediatric patients: the experience of a tertiary children's hospital COVID-19 and multisystem inflammatory syndrome in children and adolescents Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units A minimal common outcome measure set for COVID-19 clinical research Antithrombotic Therapy in neonates and children: antithrombotic therapy and prevention of thrombosis Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy The impact of ethnicity on clinical outcomes in COVID-19: a systematic review Covid-19 by race and ethnicity: a national cohort study of 6 million United States veterans Acute chest syndrome in the setting of SARS-COV-2 infections-a case series at an urban medical center in the Bronx High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients COVID-19 and venous thromboembolism in intensive care or medical ward Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience Low-molecularweight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings ASH 2020 guidelines on the use of anticoagulation in patients with COVID-19: draft recommendations SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article The authors declare no competing financial conflicts.